Ablation of SYK kinase from primary human Natural Killer cells via CRISPR/Cas9 enhances cytotoxicity and cytokine production
J. D. Dahlvang, J. K. Dick, J. A. Sangala, E. J. Pomeroy, K. M. Snyder, J. M. Moushon, C. E. Thefaine, J. Wu, S. E. Hamilton, M. Felices, J. S. Miller, B. Walcheck, B. R. Webber, B. S. Moriarity, G. T. Hart
This study ablates SYK kinase in primary human NK cells using CRISPR/Cas9, finding it enhances cytotoxicity and cytokine production compared to other gene ablations.
bioRxiv · May 29, 2022 · PreprintImmunology